Markets DARE

Daré Bioscience (DARE) Q3 2026 Earnings Call Transcript

Logo of jester cap with thought bubble.

Image source: The Motley Fool.

DATE

Monday, Nov. 16, 2026

CALL PARTICIPANTS

  • President and Chief Executive Officer - Sabrina Martucci Johnson
  • Chief Accounting Officer - MarDee Haring-Layton

TAKEAWAYS

  • Total Revenue -- $48,000 for the third quarter, driven by research and development services and initial sales of Flora Sync LF5.
  • Net Loss -- $3.2 million, comparing to a net loss of $3.6 million in the third quarter of 2025.
  • Net Loss Per Share -- $0.18, compared to $0.28 in the prior year period.
  • Cash and Cash Equivalents -- $11.5 million as of Sept. 30, 2026, including working capital of $3.2 million.
  • Research and Development Expense -- $0.3 million, a decrease from $1.2 million reflecting lower spending across multiple development programs.
  • Selling, General and Administrative Expense -- $2.6 million, an increase from $2.5 million due to higher commercial readiness expenses and personnel costs.
  • Contra R&D Expenses -- $4.7 million for the quarter, representing nondilutive grant funding that reduces reported research and development costs.
  • DARE-LARC1 Grant Funding -- $1.5 million, received as an installment in Oct. 2026, bringing total funding under the agreement to $43.3 million.
  • Gates Foundation Grant Funding -- $852,000, received for the Ovaprene Phase III trial and DARE-NHC program, totaling $9.9 million under that specific agreement.
  • DARE to PLAY Market Opportunity -- $2 billion, representing the addressable population of 20 million women in the United States.
  • DARE to PLAY Pricing -- $99 per tube, with each tube providing approximately 10 uses.
  • Sildenafil Cream Prescriber Base -- 182 office-based providers, who have written prescriptions ahead of the commencement of fulfillment services.
  • Sildenafil Cream Geographic Reach -- 48 states and the District of Columbia, where prescriptions have been written through office-based and telehealth channels.
  • DARE to PLAY Dispensing Scope -- 28 states, representing the current licensing coverage of the outsourcing facility partner for the Nov. 2026 launch.
  • Flora Sync LF5 Geographic Reach -- 27 states, from which orders have been received since the product launch in July 2026.
  • Flora Sync LF5 Consumer Sentiment -- 4.9-star review rating, based on the initial approximately 25 consumer reviews.
  • Ovaprene Phase III Timeline -- 2027, the year management anticipates reporting top-line data from the clinical study.
  • DARE-HPV Phase II Timeline -- 2027, the period management expects for top-line results from the study involving approximately 100 women.
  • DARE to RECLAIM Commercial Target -- 2027, the targeted year for availability through the 503B compounding pathway.
  • Total Grant Awards -- $75 million, representing the cumulative nondilutive funding secured to support the development pipeline.
  • Flora Sync LF5 Retail Expansion -- early 2027, when the product is expected to launch on Amazon.
  • Patent Protection -- 2039, the year until which a new U.S. patent for DARE-HPV is expected to provide protection.
  • Product Pipeline Expansion -- early 2027, when the company expects to launch the Flora Renew and Flora Reset vulvar health products.
  • Product Revenue Outlook -- limited for the remainder of 2026, as management expects initial sales from new launches to have a minor financial impact through year-end.
  • Cumulative Gates Foundation Funding -- $60 million, representing the total nondilutive awards granted to the company from this source.

Need a quote from a Motley Fool analyst? Email pr@fool.com

RISKS

  • Haring-Layton stated, "The increase [in SG&A] primarily relates to increases in commercial readiness expenses and personnel costs and a noncash write-down of deferred offering costs," identifying a specific negative factor in quarterly operating expenses.
  • Johnson stated, "Dispensing will commence in the 28 states where the outsourcing facility is currently licensed," indicating a geographic limitation for the DARE to PLAY launch.

SUMMARY

Daré Bioscience, Inc. (NASDAQ:DARE) reported on its commercial transition and progress across its clinical pipeline during the third quarter of 2026. Management highlighted a dual-path strategy involving the commercialization of proprietary formulations through 503B compounding and the development of branded consumer health products. The company reported a significant reliance on nondilutive grant funding, totaling $75 million, to advance late-stage candidates like Ovaprene and DARE-HPV. Management indicated that commercial activities for Flora Sync LF5 and the preparation for DARE to PLAY dispensing represent a shift toward establishing a multi-product revenue profile. The company is also exploring strategic partnerships to apply its drug delivery platform technology to broader markets such as obesity and diabetes.

  • CEO Johnson stated, "Product is en route today from the 503B outsourcing facility to Medvantx, which is the mail order pharmacy, and we expect prescription dispensing to begin in November."
  • The company is exploring strategic collaborations for the DARE-IDDS drug delivery technology in chronic conditions including obesity, diabetes, and neurologic disease.
  • Management reported that the 503B regulatory pathway facilitates immediate prescription availability while clinical trials continue for a future 505(b)(2) regulatory approval application with the FDA.
  • The company stated that specialized telehealth partnerships are intended to protect product pricing and avoid the concentration risks associated with high-volume subscription platforms.
  • CEO Johnson indicated that the removal of black box warnings from menopause hormone therapy products may benefit the market introduction of the DARE to RECLAIM candidate.
  • Flora Sync LF5 was selected for the Amazon new seller recruitment program to support a planned retail launch in early 2027.

INDUSTRY GLOSSARY

  • 503B Compounding: Outsourcing facilities registered under Section 503B that manufacture large batches of medications without individual prescriptions.
  • DARE-IDDS: A programmable drug delivery platform designed for controlled release of medication over months or years.
  • Ovaprene: An investigational hormone-free, monthly intravaginal contraceptive candidate.
  • DARE-HPV: An investigational vaginal insert candidate for treating persistent high-risk human papillomavirus infection.
  • DARE to PLAY: The brand name for a proprietary topical Sildenafil Cream formulation for female sexual arousal disorder.
  • DARE to RECLAIM: An investigational estradiol and progesterone intravaginal ring candidate for menopausal symptoms.
  • XACIATO: A lincosamide antibacterial gel for the treatment of bacterial vaginosis.

Full Conference Call Transcript

Operator: Hello, and welcome to the Daré Bioscience Third Quarter 2026 Financial Results and Corporate Update Conference Call and Webcast. [Operator Instructions] Note that this webcast is being recorded at the company's request, and a replay will be made available on the company's website following the end of the event. Joining us today from Daré Bioscience are Sabrina Martucci Johnson, President and Chief Executive Officer; and MarDee Haring-Layton, Chief Accounting Officer. Ms. Haring-Layton, please proceed.

MarDee Haring-Layton: Good afternoon, and welcome. Today, we will review our financial results, provide updates on our commercial products and clinical pipeline and discuss the continued execution of our dual-path strategy, which involves commercializing proprietary formulations through 503B compounding while pursuing FDA approval and advancing select solutions as branded consumer health products that do not require a prescription. In all cases, our goal is to bring innovative women's health solutions to market as efficiently and as quickly as possible. I would like to remind you that today's discussion will include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Any statements made during this call that are not statements of historical facts should be considered forward-looking statements. Actual results or events could differ materially from those anticipated or implied by these statements due to known and unknown risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements are qualified in their entirety by the cautionary statements in the company's SEC filings, including our quarterly report on Form 10-Q for the quarter ended September 30, 2026, which was filed today, and our annual report on Form 10-K for the year ended December 31, 2025. Please note that the content of this call includes time-sensitive information that is current only as of today, November 16, 2026.

Daré Bioscience undertakes no obligation to update any forward-looking statements to reflect new information or developments after this call, except as required by law. I would also like to point out that when we use the term 503B compounding during this discussion, we are referring to compounding drug products by outsourcing facilities registered under Section 503B of the Federal Food, Drug and Cosmetic Act using both drug substances on the FDA's interim Category 1 list. I would now like to turn the call over to Sabrina.

Sabrina Johnson: Thank you, MarDee, and good afternoon, everyone, and thank you for joining us. At Daré, we have always believed that women's health deserves a business built around it and that the health of women is an investment-grade category. That means developing products with a scientific foundation, addressing needs that have been overlooked and creating practical ways for women to access those products. Today, you can see that strategy taking shape across our business. Flora Sync LF5 is in the market.

Prescriptions for DARE to PLAY Sildenafil cream are being written for patients across the country ahead of dispensing, and we are excited to be able to start reaching out to clinicians today to let them know that dispensing is planned to commence later this month. Two of our later-stage clinical programs are progressing towards data in 2027, and our grant-supported work is creating opportunities that we believe will extend the portfolio. Our focus is on execution, building demand through trusted health care providers, preparing commercial supply, moving our studies forward and securing external support that helps us do more with our capital. For more than 10 years, Daré has been building towards this moment.

We have the science, we have the commercial opportunities, and our job now is to turn them into a business that delivers for women and our shareholders. To start, I think it's important to highlight the progress we have made over just the past 6 months. We launched Flora Sync LF5, opening our first direct-to-consumer revenue channel. We added MyMenopauseRx as a specialized telehealth option for DARE to PLAY Sildenafil Cream. We initiated the DARE-HPV Phase II study and announced a new U.S. patent expected to provide protection into at least 2039. We published new peer-reviewed Sildenafil Cream data in postmenopausal women and in men, expanding our evidence-based approach. We secured additional nondilutive support for DARE-LARC1 and DARE-PTB2.

And our work on the DARE-IDDS drug delivery platform underlying the DARE-LARC1 technology has supported exploratory collaboration discussions around applications in obesity, diabetes and other chronic conditions. And today, we've announced that DARE to PLAY Sildenafil Cream is en route to Medvantx, the central mail order pharmacy handling prescription fulfillment to support dispensing planned to commence this month. I will discuss these areas in more detail, beginning with the continued national attention on women's health and why that matters to our development strategy and of course, what it means that DARE to PLAY Sildenafil Cream is en route to Medvantx to start dispensing.

The new executive order on women's health calls for a dedicated NIH Women's Health Division and a White House Women's Health Task Force. The goals include better coordination of research and federal action with an emphasis on translating discoveries into improved care for women throughout their lives. We view this as a continuation of an important national focus. Across successive administrations, women's health has been recognized as an area that requires attention, investment and action. That continued attention may create additional nondilutive funding and collaboration opportunities. And that has been central to our development strategy in helping us move programs forward while limiting shareholder dilution.

Across our portfolio, we have been awarded more than $60 million from the Gates Foundation, $10 million through ARPA-H and more than $5 million through NIH and NICHD-supported programs. In October, we received $1.5 million of installment under our grant agreement for DARE-LARC1, bringing total funding received under that agreement to approximately $43.3 million. We also received approximately $852,000 under our $10.7 million Gates Foundation grant for the ongoing Ovaprene Phase III clinical trial and DARE-NHC, which is our nonhormonal contraceptive program, bringing total funding received under that agreement to approximately $9.9 million. This funding allows us to develop a broad portfolio while directing other capital towards commercial execution and priorities outside of these funded programs.

Turning to our commercial activities. Let me start with Flora Sync LF5, which is the first product in our DARE to RESTORE portfolio. Flora Sync LF5 is a nonhormonal probiotic vaginal capsule designed to support vaginal microbiome balance, moisture and comfort. It's available without a prescription, and our first product sales began in July. What differentiates Flora Sync LF5 is the science behind it. Flora Sync LF5 was evaluated in a randomized clinical study involving 100 women with results published in a peer-reviewed journal. That level of product-specific clinical research is unusual in a category where consumers frequently encounter products with limited supporting evidence. We believe this creates meaningful commercial potential.

There are an estimated 46 million sexually active women in the U.S. aged 15 to 49 and one survey found that approximately 65% of women aged 18 to 65 feel insecure about their vaginal scent. We are still in the early stages of commercialization, and our priority is disciplined execution. Our initial commercial focus has been clinician education and sampling. We are introducing the product to women's health providers, explaining the product-specific clinical research and giving them an opportunity to become familiar with it. We are also beginning to receive orders from practices that want to make the product available for purchase in their offices.

That creates a direct connection between a provider's recommendation and a woman's ability to access the product. Our objective is to turn those initial introductions into continued recommendations, office purchases and repeat consumer demand. That's the commercial foundation we are building. And we are seeing evidence that this approach is working. While the revenue in the first month is not material in the early stages of launch, we're looking at other indicators that we believe can be predictive of future performance. Specifically, we're looking at geographic reach. Flora Sync LF5 orders have come from 27 states. We're looking at provider traction, and we have received our first provider office reorder.

Customers are also telling us that they purchased Flora Sync LF5 after receiving a recommendation or a sample from their health care provider. These are the connections our commercial strategy is designed to create, clinicians introducing the product, women making a purchase and practices returning to order again. Early consumer feedback has been very positive with a 4.9-star review rating after the initial approximately 25 reviews. As we plan for 2027, we are also evaluating additional retail channels for product discovery and reorder so that women may first hear about Flora Sync LF5 from their clinician or social media and then choose the purchasing channel that's most convenient for her. That includes working with Amazon.

We were thrilled that Flora Sync LF5 was selected by Amazon for their new seller recruitment program, and we are looking forward to making the product available on Amazon in early 2027. We're also pleased to be expanding the DARE to RESTORE brand family to include Flora Renew and Flora Reset, a vulvar mask and cleanser, both anticipated in early 2027. And I'm excited, no pun intended to turn to DARE to PLAY Sildenafil Cream, our proprietary topical Sildenafil Cream formulation designed specifically for women, which we are bringing to market in collaboration with the 503B registered outsourcing facility.

Product is en route today from the 503B outsourcing facility to Medvantx, which is the mail order pharmacy, and we expect prescription dispensing to begin in November. Over the last several months, our 503B facility partner has been preparing for this day, preparing to provide supply at commercial scale. And I want to spend a moment on what that means. DARE to PLAY Sildenafil Cream is not made at a compounding pharmacy one tube at a time on an individual prescription basis. We have been preparing for commercial scale production at a registered outsourcing facility operating under pharmaceutical good manufacturing practice requirements.

That manufacturing process is an important part of being able to supply the product consistently at the scale that the demand requires. We know women and providers are waiting, so it is rewarding that we can start reaching out to them today to let them know that dispensing is planned to commence later this month. The underlying need remains substantial with an estimated 20 million women in the United States alone experiencing symptoms of low or no sexual arousal. At a price of $99 per tube, which provides about 10 uses, the estimated addressable population of 20 million women represents a total market opportunity of approximately $2 billion.

Even modest market penetration could create meaningful commercial value in an area with limited female-specific options. We're also continuing our dual-path strategy. The 503B regulatory pathway provides a way to make the formulation available by prescription now while we continue engaging with the FDA on the Phase III development program and pursuing potential approval through the 505(b)(2) regulatory pathway. While we have been preparing for dispensing, our provider outreach has been translating into written prescriptions. 182 office-based providers, not including telehealth, have already written DARE to PLAY prescriptions before the product is even available. If we include both office-based providers and telehealth, prescriptions have been written across 48 states and the District of Columbia.

Clinicians can also stock and dispense DARE to PLAY directly from their offices. And during the sexual health conference that just happened this past weekend, the first such order was received. What matters is that engagement is coming through both access channels. Office-based providers can introduce the product through an established clinical relationship. Telehealth gives women another way to connect with the provider and obtain a prescription. And while it's still early, I'm encouraged by what we are seeing in terms of geography of prescriptions being written and a healthy split between office providers and telehealth as well as repeat prescriptions from providers. Dispensing will commence in the 28 states where the outsourcing facility is currently licensed.

And once dispensing begins in those states, the facility can advance the licensing process in the remaining states. We appreciate those office-based providers who wrote prescriptions for their patients and the women who have already completed their telehealth visit so that they can be the first to try DARE to PLAY Sildenafil Cream as dispensing commences. The geographic breadth and the participation from both office-based clinicians and telehealth are encouraging, and we expect that interest is what converts into product access and revenue. We are building awareness in the places where clinicians and women are already having conversations about women's health.

That includes clinician meetings such as those hosted by The Menopause Society, HERmedicine as well as events like WME and STIMULATE that connect us with consumers, sexual health specialists and other influential voices. Encouraging examples came at The Menopause Society meeting and the Nurse Practitioners in Women's Health meetings, where thought leaders independently discussed our products on stage, importantly, without being asked or paid by Daré to do so or they live streamed from our exhibit booth. While anecdotal, it's a meaningful signal. It suggests our products are becoming part of the clinical conversation beyond our own reach. And that is visibility that can turn into recommendations and access.

Each interaction creates an opportunity to connect women with our products and build an ongoing relationship. We're often asked about expansion to national subscription product fulfillment channels, those large telehealth platforms that have a model centered on high-volume, low-price access. Those platforms are built for commodity products and pricing, whereas we're building reach across several channels that we control or that align with our strength. The DARE Health Hub, which is our own telehealth and pharmacy pathway powered by Medvantx, which keeps the patient relationship and refill experience with us. Patients and providers, any licensed prescriber can prescribe DARE to PLAY or stock it and sell it through their offices.

Telehealth companies that do not sell their own white label compounded products are also a great channel. Our collaboration with MyMenopauseRx is an example of that. A telehealth practice dedicated to perimenopause and menopause care serves women who are already seeking care and who value evidence-based options. We are pursuing additional similar collaborations, so stay tuned. This approach extends the DARE to PLAY brand across multiple platforms instead of tying it to just one. We believe it protects our pricing, avoids concentration risk and builds the clinical familiarity that sustains the brand's value over time. We remain open to and continue to evaluate other types of partners on terms that preserve the brand and its economics.

That brings me to the connection between our commercial activities and our development pipeline. When we engage with clinicians, we are discussing needs they see across their practices. That uniquely distinguishes Daré Bioscience and our corporate brand with them. Vaginal health may be the starting point, but those conversations can extend quickly to sexual health, contraception, menopause, persistent high-risk HPV infection, the therapeutic gaps that they are looking to solve and our portfolio reflects that breadth, and we believe it's well received. Ovaprene is our investigational hormone-free monthly intravaginal contraceptive currently in a pivotal Phase III study. DARE-HPV is in a Phase II study for persistent high-risk HPV infection.

And DARE to RECLAIM is our estradiol and progesterone intravaginal ring with availability through the 503B compounding pathway targeted for 2027. With the FDA initiating the removal of the black box warnings from menopause hormone therapy products in November 2025, that category is reopening after 2 decades of undertreatment. And currently, DARE to RECLAIM would be the only clinically studied product delivering both hormones in a once-a-month vaginal format, that's exciting. Each program has its own development requirements and commercial path and what they share is a focus on needs that women and their health care providers continue to identify is underserved.

I also want to highlight one of the areas of the development pipeline that we believe has significant potential, and that is the DARE-IDDS platform, which is our programmable drug delivery platform. Because it is preclinical, we often don't discuss it on these calls, but it gets a lot of attention at drug delivery conferences. DARE-IDDS is the underlying drug delivery implant technology behind DARE-LARC1, our grant-supported contraceptive program. It's designed to remotely control how much drug is released and when over a period of months to years. That type of drug delivery tunability could have broad application across a range of chronic conditions.

The value potential is being noted, and we are beginning to explore strategic collaboration in obesity, diabetes, hormone therapies and neurologic disease, including potential applications with GLP-1 medicines. For Daré, this creates an important potential opportunity to extend the value of our grant-supported research into the development of new therapeutic candidates and into major markets that are getting serious attention. We have made significant progress on the commercial front, from the ongoing launch of Flora Sync LF5 for preparing for DARE to PLAY Sildenafil Cream prescription dispensing this month. We are also building the pipeline to support future commercial growth with DARE to RECLAIM, Ovaprene, and DARE-HPV.

These programs represent opportunities to expand our portfolio through the provider relationships and commercial platform that we are establishing today. Our earlier stage programs provide additional opportunities over time. As I've noted, they include work in contraception, as well as preterm birth and other areas of women's health where we believe differentiated products could address important needs. And as I just highlighted, the IDDS platform technology could expand our reach beyond conditions that solely affect women. As with our late-stage portfolio, we're using external funding and collaborations to support development where possible. I'd now like to hand the call back to MarDee for a review of our financial results.

MarDee Haring-Layton: Thank you, Sabrina. We ended the third quarter with approximately $11.5 million in cash and cash equivalents as of September 30, 2026, and working capital of approximately $3.2 million. Total revenue for the third quarter was approximately $48,000 compared with approximately $2,000 in the third quarter of 2025. Revenue primarily reflected research and development services. Third quarter revenue also included initial sales of Flora Sync LF5, which began in July. Selling, general and administrative expenses were approximately $2.6 million compared with approximately $2.5 million in the third quarter of 2025.

The increase primarily relates to increases in commercial readiness expenses and personnel costs and a noncash write-down of deferred offering costs, partially offset by decreases in general corporate overhead expenses and professional services. Research and development expense was approximately $0.3 million compared with approximately $1.2 million in the prior year period. The decrease in expenses primarily reflected lower spending across several development programs, partially offset by increased costs related to the DARE-HPV program and decreased contra R&D expenses associated with direct program costs for grant-supported programs. Our R&D expenses reflect the impact of nondilutive funding we received.

Our low third quarter R&D expense should be considered in that context rather than as a measure of the development activity taking place across our portfolio. Net loss for the quarter was approximately $3.2 million compared with approximately $3.6 million in the third quarter of 2025. I encourage investors to review our quarterly report on Form 10-Q for a more detailed discussion of our financial results, grant agreement, liquidity and capital resources as well as the risks associated with our business. Back to you, Sabrina.

Sabrina Johnson: Thank you, MarDee. The priorities ahead are clear. We're working to build repeat demand for Flora Sync LF5 and to begin dispensing DARE to PLAY Sildenafil Cream this month. The provider engagement, written prescriptions and early office orders, as we have discussed, give us a solid base to build from, and the next step is translating that activity into sustained commercial performance. At the same time, we're moving the Ovaprene and DARE-HPV clinical studies toward readouts on both programs in 2027. Nondilutive funding continues to support that work and our earlier stage programs, and DARE-IDDS gives us an additional opportunity to explore the value of potential programmable drug delivery across a broad set of chronic conditions.

Our business now includes a product in the market, another preparing for dispensing this month and a pipeline that can support future growth. We intend to connect those opportunities through focused execution, trusted provider relationships, and disciplined investment. That's how we're building Daré Bioscience, a company focused on bringing scientifically supported options to women and creating long-term value as those options reach the market. I will now turn the call back to the operator for questions.

Operator: [Operator Instructions] Your first question comes from the line of Jeffrey Cohen with Ladenburg Thalmann.

Jeffrey Cohen: Congrats on the progress. 2 areas in particular. I guess firstly, could you talk about Flora Sync LF5? Talk about the channels there, or the perceived channels in the short term will be initially through your Health Hub exclusively, and then some expansion into Amazon early in '27? Are there other channels that you're thinking about at the moment?

Sabrina Johnson: Yes, that's a great question. So regarding Flora Sync LF5, you've summarized the near-term initiatives perfectly, which is right now, the product is available through the DARE Health Hub, as well as in clinician offices. So we do have clinician offices that have begun to stock and sell the product directly in their offices. So those are both great channels for us. Amazon is the first broad retail channel that we are going to be available on. And as we mentioned, we're really excited about how this came to be.

We've been looking at where women go for products like this, particularly as we mentioned, we want to make sure that when they get that recommendation from their healthcare provider or maybe they see it online, we want to make sure that they have available, right, a purchasing channel that's most convenient for them. And Amazon has a fantastic new seller recruitment program where they actually -- they look for brands that they think have exciting potential and meet the needs of the demographics that they serve. And so we were really thrilled that there was a match for not just like Flora Sync LF5, but as we extend the DARE to RESTORE brand family.

So yes, that's a channel that we are working on for early 2027. In addition, though, we are looking at other channels, right? We want to make sure that wherever she hears about this, it's really easy for her to get access to it. So those could be other online channels where products like this would be available, and this would be a really great fit in terms of demographics of the people that buy through those channels, as well as we are looking at different -- think of it as like brick-and-mortar retail options as well for later rollout.

Jeffrey Cohen: Got it. Would you anticipate that Renew and Reset to follow in those steps with similar channels as Flora?

Sabrina Johnson: Yes. Yes, 100%, yes.

Jeffrey Cohen: Okay. And then secondly, I wanted to jump back to DARE to PLAY Sildenafil Cream. Could you talk a little bit about physicians and office prescribers there as far as how that's looking and how that's rolling out, and also talk to us about those channels as well outside of office prescribers?

Sabrina Johnson: Yes. So with DARE to PLAY Sildenafil Cream, this one is prescription. The Flora Sync LF5 is nonprescription. So obviously, that opens up some different channels that would not be great options for DARE to PLAY Sildenafil Cream. So DARE to PLAY Sildenafil Cream is available through the DARE Health Hub. On the DARE Health Hub, we have our own telehealth available. So if someone goes to the hub and she does not already have a prescription, she can do an asynchronous. It takes about 10 minutes -- questionnaire visit to see if DARE to PLAY Sildenafil Cream is an appropriate fit for her. So she can do that on the DARE Health Hub.

If she already has a relationship with the clinician, that clinician has a couple of options, can submit the prescription through the DARE Health Hub and have it fulfilled that way or they can also make a determination to purchase the product directly and then sell it and dispense it directly in their offices. And so that's a channel that's available as well, and we have a provider already set up to do that, and there'll be others. We're also, though, looking at other, as I mentioned, other opportunities to make -- for the product where, again, women are going to get their products. So one collaboration that we highlighted today was with MyMenopauseRx.

That's an example of a telehealth practice that does not sell any products, but they really focus on perimenopause and menopause care services to women who are seeking them and who really value their evidence-based options. So I expect to see other relationships like that, that we are pursuing and are starting to set up. The other is really looking at, again, different places where women are going to get products like this. We talked a little bit about different types of national subscription models, but those are varied in their approach in how they're set up and the kind of products that they offer.

So there are some of those models that could be appropriate for this product as well. And bottom line is we want to make sure that DARE to PLAY Sildenafil Cream is -- meets a few criteria. It's available where she is conveniently going to get the product. But then it also ties to what we are focusing on for the product, right, where we have the credible science, we want to protect our pricing. We want to avoid any kind of concentration risk and we want to make sure that it's building on what really distinguishes this product, which is the clinical data and the clinical comfort behind it. So more to come. So stay tuned.

Operator: Your next question comes from the line of Kemp Dolliver with Brookline Capital Markets.

Brian Kemp Dolliver: First couple of questions Sildenafil, or if you prefer DARE to PLAY. What's the existing market size since there are a couple of competing products on the market?

Sabrina Johnson: Yes. In terms of the -- there's no competing product in the sense that there is literally another product that has the clinical evidence. So this is really a first of its kind in terms of having demonstrated that it increases blood flow within 10 to 15 minutes of application and that it has the data indicating an improvement in arousal response using clinically validated FDA-reviewed endpoints. So it's very much unique in that perspective. In terms of 503A compounded or compounded Sildenafil Cream, they are available. They are out there. They're really not comparable to this product. And that really comes across when we're talking to both women and health care providers in terms of what they're looking for.

There are no data in terms of -- it's not like IMS data or IQVIA data, as we would say now, in terms of where you can go and find that kind of prescription level marketplace data. What we do know and what I highlighted is that through the work we've done, and this has been really backed in other studies around sexual health. There are around [indiscernible] million women estimated in the United States that are not happy with their physical arousal response. They're experiencing symptoms of low or no sexual arousal, physical in nature.

And so when we look at that and then we take the price of the tube, which is about $100, $99 per tube, that's how we get at that total market opportunity of approximately $2 billion. In terms of sizing the total addressable market, that's really the best we can do right now with the data that are available.

Brian Kemp Dolliver: Also, how many states allow physicians to prescribe and dispense prescription drugs? I mean because honestly, there are very few countries on the planet that allow that. And I'm sure you're following the law. So I'm curious if this is how the size of this channel.

Sabrina Johnson: Yes. So it's really -- so first of all, from a 503B outsourcing facility, it's actually one of the reasons that the 503B outsourcing facility regulations were put into place for a recognition that hospital systems and clinician practices, there may be certain medicines that it makes sense for them to have available and to provide at a larger scale than what would be allowed through 503A pharmacy compounding on a named individual, named patient basis. So that's really one of the things that it was really designed for. In terms of where that can happen today, it really is based on, as you noted, kind of state-level regulations.

But really the key regulation behind that is where the 503B outsourcing facility is licensed to operate that, first and foremost, is where we have to focus our attention. And right now, that's 28 states.

Brian Kemp Dolliver: Great. And the last question, as you roll out these products, are you going -- I forget if you're going to be carrying the inventory and holding it on your books or if it's strictly going to be at the compounding pharmacy?

Sabrina Johnson: It's a little bit different if we're talking about DARE to PLAY Sildenafil Cream versus the DARE to RESTORE Flora Sync LF5 family of those products. When we're talking about those products, that is our inventory. Those are nonprescription products and that product inventory is ours. When we're talking about DARE to PLAY Sildenafil Cream, that is not our inventory. We are not the 503B outsourcing facility. So that inventory belongs to that 503B facility. And it's a great opportunity to talk a little bit about what one could expect to see in terms of our financial statements, right, when it comes to DARE to PLAY Sildenafil Cream, it's really going to be that net of the cost associated.

That's really what we would be receiving. So it's net of the cost of the 503B outsourcing facility. It's net of the cost at the Medvantx, which think of that as both your third-party logistics and your pharmacy dispensing. So not dissimilar for what you would see for any typical prescription product. But what we'll be booking is the net proceeds, net of all that. And so that was the long answer of no, we do not hold that inventory.

Brian Kemp Dolliver: But you will on the prescription products or -- I'm sorry on the nonprescription products.

Sabrina Johnson: On the nonprescription, correct.

Operator: Your final question comes from the line of Douglas Tsao with H.C. Wainwright.

Douglas Tsao: Sabrina, I guess I'm just curious, when you think about the addition of new platforms, when you think about what something like Amazon offers versus some of the other sort of subscription-based products or platforms, is there another vertical that you think you need to add or would be advantageous?

Sabrina Johnson: It's a great question. As we take a step back, right, I'm actually at the health conference right now that's happening in Las Vegas, and I right before this call sat in on a session around longevity. And we are not in -- we don't sometimes think of ourselves in the longevity business. But when we think about the kind of things we do, we're making people's lives better. That's a lot of what that's about.

And one of the points that came out of the session that I sat in right before I stepped out to do theearnings callwas really around, Doug, this question around where are people getting their products and how do we find that balance between making sure that the solutions that people need are available to them in the places where they are going for care?

At the same time, how do we find that balance between making sure that our products are on platforms where there are other products like ours, right, clinically studied, evidence-based solutions that are trusted, but making sure that we're meeting the consumer where they are because right now, the challenge has been, right, the medicine is not necessarily keeping up with the conversation and the consumer demands. The consumer demands are there, but the solutions that are truly studied that a health care provider can get behind just as well as the consumer can get behind are not always available. And so as we're looking at different channel strategies, the short answer to your question is yes.

There are other places that we think our products should be, and we are working on those. So they're not limited to the channels that we're rolling out initially. But I also want to go back to one of the first comments I made kind of early in the call, which is about our disciplined execution. Right now, whether we're talking about Flora Sync LF5 or we're talking about DARE to PLAY Sildenafil Cream, the first thing we're doing is making sure that health care providers, clinicians and I mean clinicians writ large broadly, right, nurse practitioners, MDs, sex therapists, pelvic floor specialists, right?

The people that will come in contact with women where our products can be beneficial are hearing the clinical story and the scientific message behind the products so that they are ready, right? Think of it as even like Flora Sync is not a prescription product, but the mindset is the same. It has nice data behind it, and we want to make sure that the clinician has heard about it in a variety of channels, and that also means existing other telehealth channels. And so we're starting with that, but we will continue.

You'll continue to see us bolting on additional places where our products are available because as we continue to do the work, we find that those are places where the women who are a perfect fit for our products are going for their solutions. I think as it comes to Flora Sync LF5, Amazon is a fantastic next step for that, both because of the program that we get to be a part of and the support behind that for the brand, which will be great.

But also that is the sort of obvious, if you think about reach and breadth, next channel for this product to be available so that if she's hearing about it from her clinician or on social media, it's a very standard typical place where someone can go for a product like this.

Operator: This concludes the question-and-answer session. I would now like to turn the call back to Sabrina Johnson.

Sabrina Johnson: Thank you so much. And as we close, I just really want to share my confidence in what we're building here at Daré Bioscience and put it in perspective. For years, our team has worked to develop options around needs that women have been asking the health care industry to address. And I believe we're answering that call. There's more to do, and we're definitely, as we've been talking about, focused on execution. Our responsibility is to turn the scientific and the commercial opportunities that we've been generating and that are in front of us into a business that delivers for women and our shareholders.

And that remains our commitment as we move through the remainder of 2026 and importantly, into 2027. Thank you.

Operator: Ladies and gentlemen, this concludes today's call. You may now disconnect.

Should you buy stock in Daré Bioscience right now?

Before you buy stock in Daré Bioscience, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Daré Bioscience wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $327,620!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $959,410!*

Now, it’s worth noting Stock Advisor’s total average return is 802% — a market-crushing outperformance compared to 205% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 17, 2026.

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. Parts of this article were created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The Motley Fool
Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.
Visit Fool.com for more market news More articles by this source

Tags

Stocks Mentioned

Latest Articles

Data is currently not available